Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides

Area of Science:

• Genetics
• Molecular Biology
• Biochemistry

Background:

• Duchenne muscular dystrophy (DMD) is a lethal genetic disorder caused by mutations in the dystrophin gene.
• Antisense oligonucleotide (AO)-mediated exon skipping is a therapeutic strategy to restore dystrophin production.
• Current AO therapies have limited applicability, necessitating broader treatment solutions.

Purpose of the Study:

• To review recent preclinical developments in AO-mediated multiple exon skipping for DMD.
• To discuss the potential of multiple exon skipping to address a wider range of DMD mutations.
• To identify remaining challenges in AO-mediated multiple exon skipping therapies.

Main Methods:

• Review of preclinical studies on AO-mediated multiple exon skipping.
• Analysis of theoretical applicability of multiple exon skipping for different mutation types (deletions, duplications, nonsense).
• Evaluation of proof-of-concept studies in animal models (dystrophic dogs and mice).

Main Results:

• Multiple exon skipping could theoretically treat a high percentage of DMD patients across various mutation types.
• Systemic multiple exon skipping has been demonstrated in preclinical models.
• Optimizing truncated dystrophin protein functionality is a potential benefit of multiple exon skipping.

Conclusions:

• Multiple exon skipping represents a significant advancement in AO-based therapies for Duchenne muscular dystrophy.
• Key challenges remain, including enhancing systemic treatment efficacy (especially cardiac) and establishing long-term safety.
• Further preclinical development is crucial to overcome these hurdles and advance multiple exon skipping therapies.